Barinthus Biotherapeutics (BRNS) Q4 2025 earnings summary

Executive summary

• Announced proposed merger with Clywedog Therapeutics to focus on metabolic and autoimmune pipeline assets, expected to close in Q2 2026.

• Completed single ascending dose portion of Phase 1 AVALON trial for VTP-1000 in celiac disease; multiple ascending dose data expected H2 2026.

• Strategic refocus in January 2025 prioritized immunology and inflammation, deprioritizing infectious disease and oncology assets.

• Merger with Clywedog expected to extend cash runway through 2027, supported by existing and new investors.

Financial highlights

• Cash, cash equivalents, and restricted cash were $71.9M as of Dec 31, 2025, down from $112.4M at end of 2024, mainly due to $48.0M in operating cash outflows.

• Research and development expenses decreased to $25.6M in 2025 from $42.2M in 2024, reflecting reduced activity in legacy assets and workforce reduction.

• General and administrative expenses rose to $40.8M in 2025 from $29.7M in 2024, mainly due to unrealized FX losses and higher professional fees.

• Impairment of intangible assets was $4.7M in 2025, reflecting lower valuation implied by the merger agreement.

• Net loss attributable to shareholders was $66.5M ($1.64/share) in 2025, compared to $61.1M ($1.55/share) in 2024.

Outlook and guidance

• Multiple ascending dose data from Phase 1 AVALON trial in celiac disease expected in H2 2026.

• Merger with Clywedog expected to close in Q2 2026, with combined company renamed and listed as Clywedog Therapeutics Holdings, Inc.

• Combined company’s cash runway anticipated to extend through 2027.